Immuron CEO, Steven Lydeamore to host an investor webinar
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immuron Limited (ASX: IMC; NASDAQ: IMRN), a biopharmaceutical company based in Australia, invites investors to a live webcast hosted by CEO Steven Lydeamore on February 28, 2023, at 11:00 AM AEDT. Immuron specializes in developing oral immunotherapeutic products for gut-mediated diseases, with its flagship product, Travelan®, approved in Australia and Canada to reduce the risk of Travelers' Diarrhea. In the U.S., it is marketed as a dietary supplement. This event aims to provide insights into the company's product offerings and future plans.
Details
News Market Reaction – IMRN
The recorded move for IMRN in the trading session of this news was -0.37%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MELBOURNE, Australia, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, invites investors to join a live webcast hosted by Steven Lydeamore, CEO of Immuron Limited.
| Tuesday, 28 February 2023 at 11:00am Australian Eastern Standard Time (AEDT). To register in advance for this webinar, please follow this link: https://us02web.zoom.us/webinar/register/WN_Gum4B9IDS-S6C1eMKr0Zqw After registering, you will receive a confirmation email containing information about joining the webinar. |
This release has been authorised by the directors of Immuron Limited.
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology platform with one commercial asset generating revenue. In Australia, Travelan® is a listed medicine on the Australian Register of Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travellers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licenced natural health product (NPN 80046016) and is indicated to reduce the risk of Travellers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection in accordance with section 403 (r)(6) of the Federal Drug Administration (FDA).
For more information visit: http://www.immuron.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.